Candidate-gene association studies in rheumatoid arthritis (RA) have lead to encouraging yet apparently inconsistent results. One explanation for the inconsistency is insufficient power to detect modest effects in the context of a low prior probability of a true effect. To overcome this limitation, we selected alleles with an increased probability of a disease association, on the basis of a review of the literature on RA and other autoimmune diseases, and tested them for association with RA susceptibility in a sample collection powered to detect modest genetic effects. We tested 17 alleles from 14 genes in 2,370 RA cases and 1,757 controls from the North American Rheumatoid Arthritis Consortium (NARAC) and the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) collections. We found strong evidence of an association of PTPN22 with the development of anti-citrulline antibodypositive RA (odds ratio [OR] 1.49; ), using previously untested EIRA samples. We provide support for P p .00002 an association of CTLA4 (CT60 allele, OR 1.23;
Introduction
Rheumatoid arthritis (RA [MIM 180300]) is a common autoimmune disease characterized by chronic, destructive, and debilitating arthritis (Gabriel et al. 1999) . The etiology of RA is unknown, but it is thought to have both a genetic and an environmental basis (Firestein 2003) . Autoantibodies are detected in ∼2/3 of patients with RA and predict more-severe disease (van Zeben et al. 1992; van Jaarsveld et al. 1999; Kroot et al. 2000) . The two major types of autoantibodies used clinically to create RA subsets are rheumatoid factor (RF), which is an immunoglobulin specific to the Fc region of IgG, and anti-cyclic citrullinated peptide (CCP) antibodies, which are antibodies directed against peptides in which arginine has been posttranslationally modified to become citrulline (Schellekens et al. 2000) . These autoantibodies are strongly correlated but may represent distinct clinical subsets of RA. For decades, it has been known that HLA-DR alleles within the major histocompatibility complex (MHC) are associated with RA (Stastny and Fink 1977) and are likely to contribute ∼1/3 of the genetic risk in RA (Deighton et al. 1989; Rigby et al. 1991) . Although the MHC associations with RA are complex (Jawaheer et al. 2002; Newton et al. 2004) , the majority of the genetic signal from the MHC is explained by multiple alleles at the HLA-DRB1 locus (MIM 142857) (Hall et al. 1996; Jawaheer et al. 2002) . These alleles are known collectively as "shared epitope" (SE) alleles because of their sequence similarity within the third hypervariable region (amino acids 70-74: Leux-x-Glu-Arg/Lys [Gregersen et al. 1987] ). Non-MHC genes are likely to contribute to RA pathogenesis and disease heterogeneity but have been much more difficult to identify.
Genetic association studies of RA applied to non-MHC candidate genes have led to encouraging yet apparently inconsistent results (see Genetic Association Database Web site). One explanation for the inconsistency is insufficient power to detect modest effects in the context of a low prior probability of a true effect and the failure to assign a stringent P value to interpret significance (Hirschhorn and Daly 2005; Wang et al. 2005) . Thousands of patients are required to detect an allele with an odds ratio (OR) less than that observed for HLA-DRB1, and the vast majority of association studies of RA have been performed with !1,000 samples (notable exceptions include studies by Barton et al. [2004b] , Begovich et al. [2004] , Prokunina et al. [2004] , Kochi et al. [2005] , and Swanberg et al. [2005] ). The inconsistent results and lack of replication make interpreting the significance of these association studies a challenge, and it is difficult to determine which results are true positives and which are false positives.
In the current study, we sought to test alleles with a prior putative association with RA or other autoimmune disorders in a collection of 4,127 samples (2,370 RA cases and 1,757 controls) powered to detect modest genetic effects (Hirschhorn et al. 2002; Lohmueller et al. 2003) . Our goal was to determine which alleles replicate in our collection from Sweden and North America, thus providing evidence of a true-positive association. We first performed a thorough review of the literature on RA candidate-gene association studies, to identify alleles with suggestive (but not definitive) evidence of association with the development of RA. We also reviewed the literature to identify alleles with convincing evidence of association with autoimmune diseases other than RA, since we hypothesized that common pathogenic mechanisms may be shared among RA and other autoimmune diseases (Yamada and Ymamoto 2005) . Here, we describe our results of testing 17 alleles in 14 genes for association with RA susceptibility in two independent clinical collections consisting of Swedish or North American individuals of European descent. Our results validate the hypothesis that the R620W variant of PTPN22 (MIM 600716) is associated with the development of RF-positive (RFϩ) and anti-CCPpositive (CCPϩ) RA and provide support for an association of RA with variants in PADI4 (MIM 605347) and CTLA4 (MIM 123890).
Material and Methods

Clinical Samples
Two case-control clinical collections were used to test all 17 alleles for association between genetic variation and the development of RA. Clinical characteristics for both collections are provided in table 1. All individuals are of European descent. In total, 4,127 samples (2,370 RA cases and 1,757 controls) were available for analysis. This study was approved by the MIT Broad Institute Institutional Review Board.
The first cohort, the Epidemiological Investigation of Rheumatoid Arthritis (EIRA), is an inception cohort collected in Sweden between May 1996 and February 2001. This cohort has been described in more detail elsewhere (Stolt et al. 2003; Padyukov et al. 2004) . Briefly, a case is defined as an individual who fulfills the American College of Rheumatology (ACR) 1987 criteria for the classification of RA (Arnett et al. 1988 ) and who has never before been diagnosed with RA. For each potential case, a control subject was randomly selected from the study base, with the subject's age, sex, and residential area taken into consideration. In total, 1,530 confirmed RA cases and 881 controls were available for analysis. Low-resolution HLA typing was performed on ∼94% of the samples by use of the sequence-specific primer-PCR method (HLA-DR low-resolution kit) as described elsewhere (Olerup and Zetterquist 1992) .
The second collection is the North American Rheumatoid Arthritis Consortium (NARAC). This collection of affected sibling pairs has been described in more detail elsewhere (Jawaheer et al. 2001 (Jawaheer et al. , 2004 ; North American Rheumatoid Arthritis Consortium Web site). Briefly, a case is defined as an individual who fulfills the ACR 1987 criteria for RA and who has at least one sibling with RA. At least one sibling must have documented erosions on hand radiographs, and at least one sibling must have disease onset between the ages of 18 and 60 years. In total, 840 affected cases from 463 families were used in our analysis. Unrelated matched controls (n p ) were selected from 20,000 healthy individuals who 867 were enrolled in the New York Cancer Project (NYCP) (see New York Cancer Project Web site). Two controls were matched to a single randomly chosen affected sibling on the basis of sex, age (birth decade), and ethnicity (grandparental country/region of origin). Complete data for PTPN22 (Begovich et al. 2004; Lee et al. 2005) and partial data for CARD15 (Addo et al. 2005 ) have been published elsewhere for this cohort. PADI4 genotype data were generated at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) by use of an overlapping set of NARAC and NYCP samples: NOTE.-Details on the EIRA cohort (Stolt et al. 2003; Padyukov et al. 2004 ) and NARAC cohort (Jawaheer et al. 2001 (Jawaheer et al. , 2004 have been published elsewhere.
601 NARAC cases and NYCP controls were common to the current data set, and 1,115 individuals were unique.
In addition to these two cohorts, an additional collection ("arthritis cohort 3") of 1,417 patients with RA (with no matched controls) was used to investigate the influence of PTPN22 alleles on RA phenotype in males and females and to study age-at-onset effects. These samples were used in a case-only analysis comparing allele frequencies in autoantibody-positive (RFϩ and/or CCPϩ) disease with those in autoantibody-negative (RFϪ and/or CCPϪ) disease. Consequently, no matched controls were necessary. Patient samples were obtained from the Wichita Rheumatic Disease Data Bank (Wolfe et al. 2003) ; The Arthritis, Rheumatism and Aging Medical Information System; the National Inception Cohort of Rheumatoid Arthritis Patients (Fries et al. 2002) 
Literature Review
We reviewed the literature published in English before December 31, 2004, to identify non-MHC alleles that had results suggesting a putative association with RA. Inclusion criteria for a putative susceptibility allele were (a) location within a non-MHC gene; (b) association with RA susceptibility-that is, the presence or absence of RA (we did not include an allele when the reported association was limited to a secondary phenotype, such as disease severity, because our primary purpose was to replicate previous associations with RA susceptibility); (c) a SNP or insertion-deletion (indel) polymorphism (i.e., no microsatellite markers); (d) genotyping in at least 200 patients with RA, with samples other than EIRA or NARAC; and (e) significance at a level !.001 in one study or !.05 in two or more studies (nominal P values based on allele frequencies in cases vs. controls). We identified 1200 published association studies of RA. From these studies, we identified 10 alleles within nine genes that met our inclusion criteria for testing in our combined RA sample collection (table 2). Specific alleles at PADI4 , CTLA4 (Rodriguez et al. 2002; Vaidya et al. 2002) , IL4 (Cantagrel et al. 1999; Maksymowych et al. 2002) , SLC22A4 , MIF (Barton et al. 2003) , and TNFRSF1B (Barton et al. 2001; Dieude et al. 2002; Kyogoku et al. 2003) have been associated with the development of RA in some studies but not in others (Dahlqvist et al. 2002; Fabris et al. 2002; Huang et al. 2002; Yen et al. 2003; Barton et al. 2004b; Miterski et al. 2004; Orozco et al. 2004; van der Helm-van Mil et al. 2004; Newman et al. 2005) . Other genes (e.g., IL3 [Yamada et al. 2001] , RUNX1 ], and HAVCR1 [Chae et al. 2004] ) have demonstrated a positive association in a single study but have not yet been tested in an independent collection for replication. Only PTPN22 has been convincingly replicated in more than one independent study (Begovich et al. 2004; Hinks et al. 2005; Lee et al. 2005; Orozco et al. 2005; Steer et al. 2005; Viken et al. 2005; Zhernakova et al. 2005) , including the NARAC samples.
Our replication study was limited to those alleles with the strongest evidence of a prior association, for efficiency and to minimize multiple-hypothesis testing. We chose the CT60 variant (rs3087243) of CTLA4, rather than the serinerthreonine missense SNP at amino acid 17 (rs231775), because the CT60 variant clearly influences the risk of Graves disease and type 1 diabetes (Ueda et al. 2003) . We chose the slc2F1 (rs2073838) allele of SLC22A4 because this allele had the strongest association with RA in a Japanese population . We chose the PADI4_94 allele (rs2240340) of PADI4 because it had the strongest association in a Japanese population . IL4 did not strictly fit the criteria, but it was included in our study because it is located within the 5q31 cytokine cluster associated with inflammatory bowel disease (Rioux et al. 2001) and is in very close proximity to SLC22A4 and IL3, both of which have reported evidence of association with RA. Although alleles within FCGR3A satisfied the inclusion criteria, they were not studied further, because FCGR3A was not amenable to genotyping by use of our platform. PTPN22 has been tested in NARAC, but we included it in our analysis to replicate the result in EIRA and to explore clinically relevant RA subsets and epistatic interactions.
We also hypothesized that an allele associated with another autoimmune disease has an increased prior probability of being associated with RA-compared with a random allele chosen from the genome-on the basis of shared pathogenic mechanisms among autoimmune diseases. We selected seven alleles from five additional genes with convincing evidence of causality in either inflammatory bowel disease (CARD15 [Hugot et al. 2001; Ogura et al. 2001] , DLG5 [Stoll et al. 2004] , and IBD5 [Rioux et al. 2001; Daly and Rioux 2004]) or type 1 diabetes (SUMO4 [Guo et al. 2004] and CTLA4 [Ueda et al. 2003 ]), although previous studies have not shown an association between CARD15 and RA (Ferreiros-Vidal et al. 2003; Steer et al. 2003; Addo et al. 2005) .
Genotyping
Genotyping was performed, as described elsewhere (Gabriel et al. 2002) , by primer extension of multiplex products with detection by matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy (Tang et al. 1999) with the use of a Sequenom platform. All genotyping was performed at the Broad Institute, except for the PADI4 variant in NARAC, which was genotyped at the NIAMS. The average completeness of genotypes was 97.8% at the Broad Institute and 98.7% at the NIAMS. Using genotypes performed in replicate (n p ), we documented a consensus error rate of 0.5% 3,814 in the analyzed data. All SNPs were in Hardy-Weinberg equilibrium within individual sample collections ( ). P 1 .01
Statistical Analysis
To test our primary hypothesis (that an allele is associated with the development of RA) and secondary hypotheses (that particular alleles are associated with a related RA phenotype reported previously in the literature) in both EIRA and NARAC samples, one-tailed P values were calculated using 2-by-2 contingency tables of allele frequencies and a Fisher's exact test, and ORs were reported relative to the published "susceptibility" allele. Results from the EIRA and NARAC cohorts were combined by Mantel-Haenszel meta-analysis of the ORs (Lohmueller et al. 2003 ), because we hypothesized that a true susceptibility allele would have an effect in both populations, despite possible genetic, ethnic, or clinical differences (Ioannidis et al. 2004) . A P value of .05 was considered significant for replication of an allele with previous evidence of association (Wacholder et al. 2004 ). Prior to combining the EIRA and NARAC results, we tested for homogeneity in the ORs, using a Pearson x 2 goodness-of-fit test as described elsewhere (Lohmueller et al. 2003) . The EIRA and NARAC cohorts demonstrated P values for homogeneity 1.01 for all loci except PTPN22 ( ) .PADI4 ( ) and CTLA4 P p .0002 P p .03 ( ) demonstrated a trend toward significant dif-P p .08 ference. We also tested our primary hypothesis by using logistic regression, controlling for familial relatedness in NARAC, age, PTPN22 and SE allele status, and autoantibody status. Relatedness among siblings was handled by use of robust (Huber/White/sandwich) variance estimates (Williams 2000) . Genotype data from the NARAC cohort for two genes (PTPN22 [Begovich et al. 2004; Lee et al. 2005] and CARD15 [Addo et al. 2005] ) have been reported elsewhere. The NARAC genotypes are included here for completeness, although tests of significance were based on EIRA genotype data. Genetic models were tested using a log-linear model of sample allele frequencies conditional on disease status (see Genetic Association Models Web site). Power cal- NOTE.-The putative susceptibility allele is listed. Genotype counts in the two cohorts are expressed relative to the putative susceptibility allele, where allele "1" is the putative susceptibility allele, and allele "2" is the nonsusceptible allele. One-tailed P values were calculated on the basis of allele frequency, relative to the putative susceptibility allele. PTPN22 independently replicates in the EIRA cohort ( ), and PADI4 and CTLA4 replicate in the EIRA and NARAC cohorts combined ( ). P p .0015 P ! .05 Homogeneity between EIRA and NARAC was calculated using a Pearson x 2 goodness-of-fit test, and only PTPN22 demonstrated a P value !.01 between the two collections. All alleles demonstrated Hardy-Weinberg P values 1.01.
a NARAC data that have been published previously.
culations were performed under a multiplicative model (a p 0.01) by use of the program by Purcell et al. (2003) . Exploratory and stratified analyses for PTPN22, CTLA4, and PADI4 were tested using a Fisher's exact test and logistic regression. Stratified analyses for the association of PTPN22, CTLA4, and PADI4 with RA case/control status were performed for three sets of subgroups: male versus female, RFϩ versus RFϪ, and CCPϩ versus CCPϪ. Subsequently, RA phenotype analyses for the association of PTPN22, CTLA4, and PADI4 within each nonoverlapping subgroup included comparison of male RA cases with female RA cases, comparison of RFϩ cases with RFϪ cases, and comparison of CCPϩ cases with CCPϪ cases. In addition, RFϩ and CCPϩ cases were compared with all controls. Analysis of sex-specific effects for PTPN22 was performed by pooling the allele frequencies across all three clinical collections and comparing male RFϩ cases with female RFϩ cases (by logistic regression). Linear regression was used to test whether a genotype influenced age at disease onset. Epistatic interactions between pairs of alleles were tested among PTPN22, CTLA4, PADI4, and HLA-DRB1 SE alleles, as recently advocated (Marchini et al. 2005) , by use of logistic regression to determine whether genotype distributions were statistically different between cases and controls. High-resolution genotyping was available for NARAC, and the SE alleles included HLA-DRB1*0101, *0401, *0404, *0405, *0408, and *1001. In the EIRA cohort, HLA-DRB1*01, *04, and *10 were considered SE alleles (Fries et al. 2002) , since only low-resolution genotyping was available. On the basis of NARAC data, we estimated that the fraction of HLA-DRB1*01, *04, and *10 individuals in the EIRA cohort who carry the SE allele is ∼92%, 96%, and 81%, respectively. To estimate the false-positive rate, we implemented a Bonferroni correction of our PTPN22 results for three hypotheses (age, sex, and epistasis with HLA) and of our CTLA4 and PADI4 results for five hypotheses (age, sex, autoantibody status, and epistasis with HLA or PTPN22).
We performed a meta-analysis of all studies with published allele-frequency data for individuals of European ancestry, together with our genotype data, as described elsewhere (Lohmueller et al. 2003) . We first tested for homogeneity in the ORs across studies, using a Pearson x 2 goodness-of-fit test. When studies across all ethnic populations were analyzed together, we observed heterogeneity for IL4, TNFRSF1B, and MIF. To minimize heterogeneity, we excluded studies performed in nonEuropean populations. Among studies of individuals of European ancestry, we observed no evidence of significant heterogeneity ( ). We calculated the pooled P 1 .01 OR under a fixed-effects model (Mantel-Haenszel metaanalysis). The original hypothesis-generating publication was excluded from the meta-analysis, when applicable, to avoid bias from the null hypothesis of no effect (Hirschhorn et al. 2002) . Genotype data were available for IL4 (Cantagrel et al. 1999) , MIF (Miterski et al. 2004) , TNFRSF1B (Barton et al. 2001; Dahlqvist et al. 2002; Fabris et al. 2002; Kyogoku et al. 2003; Yen et al. 2003; van der Helm-van Mil et al. 2004) , CARD15 (Ferreiros-Vidal et al. 2003; Steer et al. 2003; Addo et al. 2005) , and CTLA4 (Barton et al. 2004b; Orozco et al. 2004 ) but were unavailable from some studies (Dieude et al. 2002; Maksymowych et al. 2002; Newman et al. 2005) . We excluded MIF data from Barton et al. (2003) , since 25% of the cases with inflammatory polyarthritis failed to develop RA. Only a single study (Martinez et al. 2005 ) has tested the PADI4_94 variant (rs2240340)-the variant was not tested by Barton et al. (2004a) . Across all studies, there were insufficient data on clinically relevant subsets of RA (e.g., subsets based on autoantibody status and sex) available to perform a more refined meta-analysis.
Results
Description of EIRA and NARAC Clinical Cohorts and Estimation of Study Power
To maximize our power to detect a true causal RA allele, we included 14,000 clinical samples from two distinct cohorts: the EIRA (Stolt et al. 2003; Padyukov et al. 2004 ) and the NARAC (Jawaheer et al. 2001 (Jawaheer et al. , 2004 . The clinical features of the EIRA and NARAC cohorts are shown in table 1. The combined resource of 14,000 total case-control samples provides good power to detect even modest genetic effects; we have 180% power to detect the published OR for 14 of the 17 alleles selected for replication and 150% power to detect an OR у1.25 for all alleles (see the "Material and Methods" section). Thus, failure to replicate in our clinical collection substantially reduces the probability that an allele is a true causal allele.
Selection of Candidate Alleles and Testing of Primary Hypothesis
To maximize further our ability to detect a true positive result, we selected alleles from the published genetic association studies of RA and other autoimmune diseases. Our goal for the literature review was to identify alleles with suggestive evidence of association with RA ( in one study or in two or more studies) P ! .001 P ! .05 or convincing association with a different autoimmune disease. Our primary hypothesis was that an allele that satisfies these criteria is associated with susceptibility to RA in our collection. Applying our inclusion criteria (see the "Material and Methods" section) to the RA and autoimmune literature, we identified 17 alleles within 14 genes with a putative association with RA or another autoimmune disease (table 2). Ten alleles within nine genes had suggestive statistical evidence in favor of an association with the development of RA. Only the R620W variant of PTPN22 had been convincingly replicated in more than one study (Hinks et al. 2005; Lee et al. 2005; Orozco et al. 2005; Steer et al. 2005; Viken et al. 2005; Zhernakova et al. 2005 ). Seven alleles within five genes had convincing evidence in favor of an association with a chronic autoimmune disease (either inflammatory bowel disease or type 1 diabetes), although previous studies have not shown an association between one of those five genes, CARD15, and RA (FerreirosVidal et al. 2003; Steer et al. 2003; Addo et al. 2005) .
To determine whether any of the 17 alleles identified through our literature review is associated with RA susceptibility (primary hypothesis), we genotyped each allele in our combined clinical collection of 14,000 casecontrol samples. For each allele, we first analyzed the cohorts individually; second, we performed a formal test for heterogeneity in the OR across the two cohorts; and third, we combined the samples in a meta-analysis to provide the best estimate of the OR (under the assumption of a homogeneous effect across cohorts). Of the 17 alleles tested, 3 replicated association, with a onetailed P value !.05 (table 2) in the combined samples: PTPN22, PADI4, and CTLA4. PTPN22 had not been tested previously in the EIRA cohort and thus represents an independent replication. The data for each of the three genes fit best under a multiplicative genetic model (compared with general, dominant, and recessive models). The CTLA4 result remained significant after we controlled for self-reported thyroiditis (with which CTLA4 demonstrates a genetic association [Ueda et al. 2003 ]) in the NARAC cohort (OR 1.19; 95% CI 1.03-1.38;
). We did observe a P value !.05 for P p .02 SUMO4 and HAVCR1, but it was for the opposite allele than the published susceptibility allele. (Because we report our results in table 2 with respect to the published putative susceptibility allele, SUMO4 and HAVCR1 NOTE.-The two categories of autoantibodies are RF and CCP. The PTPN22 allele-frequency distribution was compared among RFϩ cases, RFϪ cases, and all EIRA controls. Only RFϩ patients demonstrated a statistically significant difference in allele frequency when compared with all controls ( ). The difference between RFϩ and RFϪ cases is statistically significant ( ). We also P p .0001 P p .003 stratified EIRA patients on the basis of CCP antibody status. We found that the allele-frequency distribution in CCPϩ cases (but not CCPϪ cases) is statistically different from that in controls (P p ). The difference between CCPϩ and CCPϪ cases is statistically significant ( ). .00002 P p .0004
have ORs that are significantly !1.0 but have P values close to 1.) None of the other alleles demonstrated a significant association in these two cohorts (table 2) , even after we controlled for the effects of HLA-DRB1 and PTPN22 (data not shown).
Selection and Testing of Secondary Hypotheses
RA is a heterogeneous disease, and it is possible that an allele is associated with only a clinical subset of RA. Therefore, we used our literature review to define specific secondary hypotheses to test in our RA clinical collection, to ensure that we did not miss a positive association. Each secondary hypothesis was based on data from a previous publication that suggested a specific genetic association. The secondary hypotheses relate either to an RA subphenotype or to a specific genetic model. We defined five secondary hypotheses (with published ORs):
(1) PTPN22 is associated with RFϩ but not RFϪ disease (OR 2.0) (Begovich et al. 2004; Lee et al. 2005) ; (2) homozygotes for the PADI4 susceptibility allele are more likely to be CCPϩ than are the other genotypes combined (OR 3.25) ; (3) individuals homozygous for the putative susceptibility alleles at both SLC22A4 and RUNX1 have a marked increase in RA disease risk under a dominant (but not epistatic) model (OR 9.03) ; (4) TNFRSF1B is associated with familial RA but not sporadic RA (OR 1.69) (Barton et al. 2001; Dieude et al. 2002) ; and (5) IL3 is associated with RA in females with earlyonset disease (OR 1.89) (Yamada et al. 2001) . No other secondary hypotheses with published statistical evidence were identified for the remaining 11 alleles. Given the high ORs, we have 180% power to detect each hypothesis, with the exception of the one regarding SLC22A4 and RUNX1, for which there is limited power to detect an association. We modified the hypothesis to ask whether individuals homozygous at RUNX1 and either heterozygous or homozygous at SLC22A4 ("susceptible") were at an increased risk of developing RA, compared with all other individuals ("nonsusceptible"). We have 180% power to detect this hypothesis (estimated OR 1.52, on the basis of genotype data from Tokuhiro et al. [2003] ).
Each of our five secondary hypotheses was tested in the EIRA and NARAC clinical collections. As shown in table 3, we replicated the finding that PTPN22 is associated with RFϩ disease but not RFϪ disease, using the previously untested EIRA cohort ( in P p .0001 EIRA). We extend this observation in autoantibodypositive disease to include an association with CCPϩ cases but not CCPϪ cases (table 3) in the EIRA cohort, which is consistent with previously published clinical observations that these autoantibodies are strongly correlated. Using data combined from EIRA and NARAC, we observe a trend toward an association with PADI4 and anti-CCP antibody status, as previously suggested, but this was not statistically significant (table 4). We found no significant evidence to support an additive model between SLC22A4 and RUNX1 (table 5), although we have limited power to detect the model proposed by Tokuriho et al. (2003) , given the allele frequencies observed in our population; we found no significant evidence to support an association between IL3 and RA in females with early-onset disease (table 6); and we found no significant evidence for an association of TNFRSF1B with familial RA, represented by the NARAC affected sibling pairs (table 2) .
Exploring Novel Hypotheses for PTPN22
Having established clear evidence for an association of RA susceptibility with PTPN22 in our samples, we sought to explore whether the R620W variant is associated with a clinically relevant subset of RA. Each exploratory hypothesis was defined on the basis of phenotypes of clinical relevance to RA, as established through epidemiological studies, animal models, or con- vincing genetic studies of the HLA-DRB1 SE alleles. The hypotheses were considered exploratory because no suggestive genetic association for the individual genes had been reported previously (in contrast to our primary and secondary hypotheses). Our three exploratory hypotheses include: (1) the allele has a greater effect in one sex than in the other, (2) the allele influences age at disease onset, and (3) the allele is epistatic with HLA-DRB1 SE alleles.
In an analysis of EIRA and NARAC cases, together with a separate case-only collection of 1,417 RA cases ("arthritis cohort 3" ]), we found modest support that the PTPN22 susceptibility allele has a greater effect in males than in females ( ) (table P p .03 7). This effect was most prominent in the EIRA cohort and the arthritis cohort 3. We also observed an age-atonset effect for PTPN22: carriers of the susceptible T allele develop RA 2 years earlier than do those not carrying the allele (T/T or C/T mean ‫ע‬ SD, 48.2 ‫ע‬ 14.0; C/C, 50.1 ‫ע‬ 14.3;
). We found no evidence P p .004 to support an epistatic interaction between PTPN22 and SE alleles (data not shown) in the EIRA cohort, which is consistent with previously published reports on NARAC (Begovich et al. 2004) . After application of a conservative Bonferroni correction for three hypotheses, the sex effect is no longer significant at a P value !.05, whereas the age-at-onset effect remains significant ( ) . P p .012
Stratified Analyses to Explain Heterogeneity for PTPN22, CTLA4, and PADI4
We observed a difference in the magnitude of the genetic effect, as measured by the ORs, between the EIRA and NARAC cohorts: PTPN22 is stronger and more significant in NARAC than in EIRA, and CTLA4 and PADI4 are only significant in the NARAC cohort. As part of our initial analysis, we formally tested for heterogeneity between the ORs of the two cohorts, and we observed a clear significant difference for PTPN22 ( ) and a trend toward significance for PADI4 P p .0002 ( ) and CTLA4 ( ). Because the ascer-P p .03 P p .08 tainment criteria and clinical characteristics between the two cohorts are distinct, we sought to explore whether a clinically relevant RA subset or an epistatic interaction might explain the difference in observed ORs. Therefore, we stratified our analysis by available clinically relevant subsets of RA (sex, autoantibody status, and age at onset) and epistasis with HLA and/or PTPN22.
Stratified analyses demonstrated that CTLA4 has a stronger association in patients positive for RF or CCP autoantibodies (table 8) . This effect is most apparent in a pooled analysis of EIRA and NARAC, when CCPϩ cases are compared with all controls (OR 1.18; 95% CI 1. 07-1.31; ). The result remains significant P p .0006 after a Bonferroni correction for five hypotheses (P p ). No other clinically relevant subset demonstrated .003 a significant association, and we found no evidence of epistasis between any two combinations of CTLA4 with HLA or PTPN22 alleles and PADI4 with HLA or PTPN22 alleles (data not shown). Overall, however, we were unable to find any variable(s) to explain the OR differences for the three genes between the EIRA and NARAC cohorts.
Meta-Analysis with Published Data
Alleles with modest impact on disease susceptibility may be missed by any single study. We therefore performed a meta-analysis, combining our results with previously published results for individuals of European descent, to determine whether subtle effects across all published studies could be detected, under the hypothesis that a true susceptibility allele has an effect in different populations despite possible ethnic or clinical differences. The results, shown in table 9, fail to demonstrate an association of RA with CARD15, IL4, MIF, or TNFRSF1B. In contrast, the meta-analysis of previously published data with our data for CTLA4 (table  10) and PADI4 (combined OR 1.12; 95% CI 1.03-1.23 [Martinez et al. 2005] ) demonstrates continued evidence of association with RA.
Discussion
Genetic association is a powerful statistical methodology to identify variants that influence the risk of developing a common disease such as RA. However, inconsistent results across multiple studies make it difficult to interpret which results represent true-positive association and, therefore, which genes truly influence the risk of RA. One explanation for the inconsistent results is insufficient power to detect modest effects in the context of a low prior probability of a true effect (Hirschhorn and Daly 2005; Wang et al. 2005 ). To overcome this NOTE.-We performed a case-only analysis stratified on the basis of sex and RF status. Pooled analysis of the OR of all three collections demonstrated that the effect of the PTPN22 susceptible T allele is greater in males (OR 1.76) than in females (OR 1.19), a difference that is statistically significant by logistic regression ( ). P p .03 limitation, we designed a study to test alleles with an increased prior probability of disease association in a sample collection powered to detect modest genetic effects. Our results confirm the association of PTPN22 with autoantibody-positive RA and provide support for an association with CTLA4 and PADI4. Stratified analysis of our data reveals a novel association with age at onset (PTPN22), sex (PTPN22), and autoantibodypositive RA (CTLA4), results that need to be replicated in an independent data set.
Our results in the EIRA cohort, together with other replication studies (Hinks et al. 2005; Lee et al. 2005; Orozco et al. 2005; Steer et al. 2005; Viken et al. 2005; Zhernakova et al. 2005) , confirm the hypothesis originally described by Begovich et al. (2004) in the NARAC cohort that the PTPN22 R620W variant influences the risk of autoantibody-positive RA. We extend the finding that PTPN22 is associated with RFϩ disease to include CCPϩ disease. This result is not surprising, given the strong correlation between RF and CCP status. However, it is interesting to note that a more significant result was obtained with CCP status (table 3) , which is consistent with the clinical observation that CCP is a more specific marker for RA than is RF (Schellekens et al. 2000) . Together, these results provide the most convincing evidence to date of a non-MHC gene that influences the risk of developing RA.
Our stratified analyses of PTPN22 revealed novel associations with clinically relevant subsets of RA. We identified an association of PTPN22 with age at onset ( ), such that carriers of the susceptible allele P p .004 develop RA ∼2 years earlier than noncarriers do. We observed a similar result for the HLA-DRB1 SE alleles and age at onset ( ; data not shown). We also P p .0002 observed that PTPN22 has a greater effect in RFϩ males than in RFϩ females ( ), a result which is no P p .03 longer significant at the level when we correct P ! .05 for our three exploratory hypotheses. Recently, Orozco et al. (2005) reported a similar trend in male versus female patients with RA. Limited clinical data for RA suggest that sex differences indeed exist (Weyand et al. 1998; Kuiper et al. 2001; Tengstrand et al. 2004 ), findings corroborated by animal models of arthritis (Remmers et al. 2002; Adarichev et al. 2003; Meng et al. 2004) . These novel findings require replication in independent sample collections.
Interpreting the significance of CTLA4 and PADI4 is more challenging, but our data support the hypothesis that genetic variation within these genes influences the risk of developing RA. Our results are significant only in the NARAC cohort, although a trend toward an association with CTLA4 is noted in the EIRA cohort. Because the cohorts are clinically different, we stratified our analysis by sex, autoantibody status, and age at onset. In support of a true-positive association for the CT60 allele of CTLA4, our results are strengthened in the EIRA cohort when only CCPϩ cases are compared with all controls (combined OR 1.18; ) or P p .0006 with CCPϪ cases (OR 1.18; ). This result, if P p .007 replicated, may indicate that CTLA4 influences the development of RA only in CCPϩ patients. Our results remain significant after a formal meta-analysis with the published RA literature that includes individuals of European ancestry. Recently, Lei et al. (2005) demonstrated an association between the CT60 allele and RA susceptibility in Han Chinese (OR 1.41; 95% CI 1.10- Table 9 Meta-Analysis of IL4, MIF, TNFRSF1B, and CARD15
Allele-Frequency Data
The table is available in its entirety in the online edition of The American Journal of Human Genetics.
1.82;
), providing additional support for a P p .005 true-positive association.
An alternate explanation for the modest association of CTLA4 and PADI4 with RA in our collection is that our result is a false-positive. Possible explanations for a false-positive result include technical artifact, population stratification, or an inappropriate statistical threshold of significance. Our genotyping efficiency and accuracy argue strongly against technical artifact (see the "Material and Methods" section). Both cohorts were matched on the basis of ethnicity, which reduces the likelihood of stratification. However, it is becoming increasingly clear that subtle stratification exists even in well-matched cohorts (Freedman et al. 2004; Marchini et al. 2004) . Extensive genotyping of genomic controls (Pritchard and Donnelly 2001) , which is beyond the scope of this project, is necessary to assess the extent of stratification in each cohort. Ultimately, additional studies in sufficiently powered cohorts of patients with RA, together with an updated meta-analysis of the published literature, are required to determine definitively whether genetic variation within PADI4 and/or CTLA4 influences the risk of developing RA.
If our CTLA4 and PADI4 results in 14,000 samples are true positives, and the actual allelic OR is ∼1.10 (as indicated by the pooled analysis), then it is not surprising that smaller studies have failed to detect a statistically significant result. An allele at ∼40% population frequency with an OR of ∼1.10 under a multiplicative model requires ∼2,700 cases and ∼2,700 controls to have 80% power to detect a true-positive result (type I error rate 0.05) (see Genetic Power Calculator Web site), and previous studies were conducted with fewer samples than this (Barton et al. 2004a (Barton et al. , 2004b Orozco et al. 2004; Martinez et al. 2005) . Consistent with this explanation, previous studies have shown that the putative susceptibility alleles were marginally increased in patients with RA, but not to a level that reached statistical significance (see table 10 for CTLA4 meta-analysis).
Our finding that the majority of previous association studies in RA may represent false-positive results is consistent with the published literature of other complex genetic diseases (Ioannidis et al. 2001; Lohmueller et al. 2003) . Although it is possible that some of our results are false negatives, we have 180% power to detect the published OR in 14 of the 17 alleles selected for replication (and 150% for all alleles). We selected a nominal P value of .05 as significant, to minimize falsepositive results and to maximize our confidence in a true-positive association. On the basis of empiric and theoretical data in complex traits, others have advocated similar replication P values (Lohmueller et al. 2003; Wacholder et al. 2004 ). Furthermore, a formal meta-analysis failed to detect a subtle effect that may have been missed by our replication in the NARAC and EIRA cohorts (table 9). Although we observed no significant evidence of genetic heterogeneity across studies, we excluded individuals of non-European descent. Of note, there are no formal tests of heterogeneity in patient selection criteria, and it may be that an alternate analytic method is necessary to combine effects across studies.
Other explanations for the lack of replication in our collection include genetic, ethnic, and clinical heterogeneity across study populations and the possibility that we did not test the actual causal allele in a given gene. NOTE.-Allele-frequency data of RA cases versus controls were compared across four study populations, by use of a fixed-effects (Mantel-Haenszel) meta-analysis of the ORs. No significant heterogeneity was observed among the four studies. No data on CCP status were available from the two published studies to compare CCPϩ cases only (for which we observed a more significant result).
It is possible that a true susceptibility allele in one ethnic population has no effect in a different ethnic population ("ethnic heterogeneity"). There is little evidence to support this hypothesis (Ioannidis et al. 2004) , although a thorough evaluation is not yet possible, given the limited number of true susceptibility alleles tested across multiple ethnic populations. Differences in clinical features or ascertainment criteria across RA collections may account for the inability to replicate. For example, we observe a more significant association between RA and CTLA4 and PTPN22 alleles when CCP status is taken into consideration. In an attempt to control for clinical differences, we used our literature review to define secondary hypotheses that test for relevant subsets, but we found no evidence of association. Finally, we cannot exclude that other variants within these genes may be associated with RA. We selected alleles with the mostsignificant association from a previous study. If we assume that an allele is either the putative causal allele or in very strong LD with the causal allele, then our study design should replicate the original finding. Comprehensive testing of genetic variation within each gene may reveal alternate alleles that contribute to RA susceptibility, as recently suggested by a study of PTPN22 (Carlton et al. 2005) .
We observed a difference in the ORs between the EIRA and NARAC cohorts for PTPN22, CTLA4, and PADI4. There are two possible explanations for the differences. First, the effect in NARAC and EIRA could actually be the same, with the different ORs simply reflecting sampling variance across the two populations. This is clearly not the case for PTPN22, which demonstrates a statistically significant difference between the two cohorts. Second, the OR in NARAC and EIRA could indeed be different as a result of ascertainment, clinical severity, "genetic loading" of affected sibling pairs, or an unmeasured variable. Our stratified analyses failed to identify any clear explanation for the difference, although we were unable to correct for disease severity, because of the lack of a suitable clinical variable in EIRA (e.g., disease activity score or radiographic erosions). The statistically significant differences in the ORs observed for CTLA4 and PADI4 are sufficiently modest such that we do not believe it is possible to determine these two association models at present. Future studies aimed at identification of covariates will be important for understanding the impact of these genes on RA clinical heterogeneity.
We did observe a P value !.05 for HACVR1 and SUMO4, but not with the published susceptibility allele. Therefore, these results may represent statistical fluctuation rather than a true-positive association. Recent data have called into question the validity of the SUMO4 association with type 1 diabetes (Park et al. 2005; Qu et al. 2005; Smyth et al. 2005) . It should also be noted that the allele frequency of the SLC22A4 variant tested is significantly lower in our collection (minorallele frequency ) than in the Japanese [MAF] ≈ 0.08 population ( ), which limits our power to MAF ≈ 0.31 detect a true association (especially under a recessive genetic model). Studies in additional populations are necessary to test whether these or alternate alleles are associated with RA.
In conclusion, our results replicate the finding that PTPN22 is associated with RFϩ RA and suggest the novel hypotheses that the allele influences age at RA onset and has a greater effect in males than in females. In addition, our study provides support for association of RA with CTLA4 and PADI4, a result that will need to be confirmed in additional studies. We find no evidence to support an association for the remaining alleles, which suggests that these alleles are not associated with RA with an OR у1.10. These results add to our understanding of the genetic basis of RA and emphasize the need for large collections of patients, updated meta-analysis, and stringent interpretation of statistical significance in future RA candidate-gene association studies.
